Prognosis of patients eligible for dapagliflozin in acute heart failure.

Sebastian CarballoJérôme StirnemannNicolas GarinPauline Darbellay FarhoumandJacques SerratriceDavid Carballo

Published in: European journal of clinical investigation (2020)

Using DAPA-HF criteria, only 27% of non-selected patients admitted for ADHF are theoretically eligible for dapagliflozin. This eligibility for dapagliflozin is associated with better outcomes. Further evaluation of the benefits of dapagliflozin in selected HF patients may be of interest. This may have implications for selection criteria in future randomized effectiveness studies.

Keyphrases

acute heart failure
end stage renal disease
ejection fraction
randomized controlled trial
heart failure
prognostic factors
insulin resistance
placebo controlled
phase ii